Immune adjuvant for cancer
AssigneeAdvanced Innovation Development Co. Ltd.
InventorsTsukasa SEYA, Misako MATSUMOTO
Life of this patent
Estimating the term…
Abstract
The present invention relates to a medicament for treating cancer or infectious disease, the medicament comprising an immune checkpoint blockade and an adjuvant composition. More specifically, the present invention relates to a medicament for cancer or infectious diseases, wherein an anti-PD-1 antibody or an anti-PD-L1 antibody is used in combination with a nucleic acid adjuvant composed of a double-stranded RNA and a single-stranded ODN.
Claims18
A method for treating cancer or infectious disease, comprising administering an immune checkpoint blockade and an adjuvant composition to a patient in need thereof,
- wherein the immune checkpoint blockade comprises an anti-PD-1 antibody or an anti-PD-L1 antibody, and
- the adjuvant composition comprises a nucleic acid adjuvant comprising a double-stranded RNA and a single-stranded oligodeoxynucleotide (single-stranded ODN) consisting of a sequence of a CpG ODN where CpG is replaced with GpC, TpC, or CpC, or a partial sequence thereof having 5 or more bases in length.
An adjuvant composition comprising a nucleic acid adjuvant comprising a double-stranded RNA and a single-stranded oligodeoxynucleotide (single-stranded ODN) consisting of a sequence of a CpG ODN where CpG is replaced with GpC, TpC, or CpC or a partial sequence thereof having 5 or more bases in length,
- wherein the double-stranded RNA is a nucleic acid comprising 2 to 4 repetitions of a nucleotide sequence having continuous 30 to 80 bases in length of a nucleotide sequence represented by SEQ ID NO:
- 1.
Dependencies are inferred from the claim text.